Atogepant for migraine in real-world clinical practice: Insights from a large multicentre study in a treatment-resistant population (GEMA project)
Gago-Veiga, Ana Beatriz ; López-Rodríguez, Ana Belén ; Sánchez Jiménez, Marina ; Iglesias Rubio, Álvaro ; Montes, Nuria ; Camiña Muñiz, Javier ; Domínguez Gallego, Marta ; Calle de Miguel, Carlos ; Latorre, Germán ; Rodríguez-Vico, Jaime ; Jaimes, Alex ; Gómez García, Andrea ; Urtiaga, Sara ; González Salaices, Marta ; Dileone, Michele ; González-García, Nuria ; Porta-Etessam, Jesús ; Cuadrado, María-Luz ; Herrero San-Martín, Alejandro ; Guerrero-Peral, Ángel-Luis ; González-Osorio, Yesica ; Casas-Limón, Javier ; Sánchez-Soblechero, Antonio ; Lozano-Ros, Alberto ; Díaz-De-Terán, Javier ; Portocarrero-Sánchez, Leonardo ; Molina-Martínez, Francisco-José ; Santos-Lasaosa, Sonia (Universidad de Zaragoza) ; Martín-Ávila, Guillermo ; Riva, Elena ; Fernández-Lázaro, Iris
Resumen: Aim
Atogepant is a novel oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for migraine prevention. This study primarily evaluated its effectiveness and safety in real-world clinical practice, focusing on patients with treatment-resistant migraine, defined according to the European Headache Federation (EHF) criteria as failure of at least three classes of preventive medications, including onabotulinumtoxinA or anti-CGRP monoclonal antibodies (mAbs).
Methods
This prospective multicentre study was conducted across 15 tertiary Headache Units in Spain. Demographic and clinical data, prior preventives, monthly headache days (MHD), monthly migraine days (MMD), and adverse events (AEs) were systematically collected at baseline, 3 months (primary endpoint), and/or 6 months (secondary endpoint).
Results
AimA total of 513 patients were enrolled (mean age 48 years; 88% women). The 3-month analysis included 455 patients, with median MHD decreasing from 21 (IQR 15-30) to 14 (IQR 6-30) and MMD from 14 (IQR 10-20) to 8 (IQR 3-15) (both p < 0.0001). A ≥ 50% reduction was achieved by 34% (MHD) and 29% (MMD), with ≥75% responses in 16% and 13%. Adverse events were mostly mild, mainly constipation (30%) and nausea (18%), and the 3-month discontinuation rate was 11.8%. Responders had shorter migraine chronicity, less analgesic overuse, and fewer prior preventive failures. Although prior inadequate response to anti-CGRP mAbs reduced the likelihood of improvement, it did not prevent meaningful benefit. At analysis, 151 patients had reached the 6-month visit, showing further improvement (MHD 10 [IQR 5-20]; MMD 6 [IQR 4-12]) and fewer adverse events.
Conclusions
Atogepant showed robust real-world effectiveness and good tolerability in a large, treatment-resistant migraine cohort, with clinically meaningful improvement at 3 months and incremental benefit in the subgroup evaluated at 6 months. Lower migraine chronicity and fewer prior preventive failures were associated with better outcomes, supporting the earlier introduction of anti-CGRP therapies in clinical practice.
Idioma: Inglés
DOI: 10.1177/03331024261431337
Año: 2026
Publicado en: CEPHALALGIA 46, 4 (2026), 1-15
ISSN: 0333-1024
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/i-PFIS-IFI15-00158
Tipo y forma: Article (Published version)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
Exportado de SIDERAL (2026-04-22-08:33:09)
Visitas y descargas
Atogepant is a novel oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for migraine prevention. This study primarily evaluated its effectiveness and safety in real-world clinical practice, focusing on patients with treatment-resistant migraine, defined according to the European Headache Federation (EHF) criteria as failure of at least three classes of preventive medications, including onabotulinumtoxinA or anti-CGRP monoclonal antibodies (mAbs).
Methods
This prospective multicentre study was conducted across 15 tertiary Headache Units in Spain. Demographic and clinical data, prior preventives, monthly headache days (MHD), monthly migraine days (MMD), and adverse events (AEs) were systematically collected at baseline, 3 months (primary endpoint), and/or 6 months (secondary endpoint).
Results
AimA total of 513 patients were enrolled (mean age 48 years; 88% women). The 3-month analysis included 455 patients, with median MHD decreasing from 21 (IQR 15-30) to 14 (IQR 6-30) and MMD from 14 (IQR 10-20) to 8 (IQR 3-15) (both p < 0.0001). A ≥ 50% reduction was achieved by 34% (MHD) and 29% (MMD), with ≥75% responses in 16% and 13%. Adverse events were mostly mild, mainly constipation (30%) and nausea (18%), and the 3-month discontinuation rate was 11.8%. Responders had shorter migraine chronicity, less analgesic overuse, and fewer prior preventive failures. Although prior inadequate response to anti-CGRP mAbs reduced the likelihood of improvement, it did not prevent meaningful benefit. At analysis, 151 patients had reached the 6-month visit, showing further improvement (MHD 10 [IQR 5-20]; MMD 6 [IQR 4-12]) and fewer adverse events.
Conclusions
Atogepant showed robust real-world effectiveness and good tolerability in a large, treatment-resistant migraine cohort, with clinically meaningful improvement at 3 months and incremental benefit in the subgroup evaluated at 6 months. Lower migraine chronicity and fewer prior preventive failures were associated with better outcomes, supporting the earlier introduction of anti-CGRP therapies in clinical practice.
Idioma: Inglés
DOI: 10.1177/03331024261431337
Año: 2026
Publicado en: CEPHALALGIA 46, 4 (2026), 1-15
ISSN: 0333-1024
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/i-PFIS-IFI15-00158
Tipo y forma: Article (Published version)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
Exportado de SIDERAL (2026-04-22-08:33:09)
Permalink:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
articulos > articulos-por-area > medicina
Notice créée le 2026-04-22, modifiée le 2026-04-22